Study examines the cost-effectiveness of a targeted immunotherapy for lung cancer

FHS
May 31, 2024
2:43 am

Many countries with national healthcare systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health benefits.

Novel Drug Eases Disease Activity in Dermatomyositis

An investigational monoclonal antibody targeting interferon beta (IFNβ) led to rapid and pronounced reductions in disease activity in adults with dermatomyositis, a randomized phase II

January 16, 2025

Updated: Novo Nordisk’s semaglutide injection reduces cardiovascular events by 20% in vast SELECT trial

Novo Nordisk’s semaglutide injection reduced major adverse cardiovascular events by 20% in obese or overweight patients without diabetes, further bolstering the case for more widespread

August 9, 2023

Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy

Lilly’s Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide 1 (GLP-1) receptor agonist while Novo’s Wegovy is a GLP-1 receptor agonist.

December 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.